Brief: Avacta Group Reports Platform-Validating Data With Faridoxorubicin
25/06/2026 08:06
BRIEF-Avacta Group Reports Platform-Validating Data With Faridoxorubicin June 25 (Reuters) - Avacta Group PLC AVCT.L:
PLATFORM-VALIDATING DATA WITH FARIDOXORUBICIN
RESPONSES OBSERVED IN PATIENTS WITH VERY LOW FAP EXPRESSION DESPITE TUMOR RESPONSE
FURTHER DATA UPDATES EXPECTED IN Q3 2026